Xalkori crizotinib regulatory update

EMA’s CHMP recommended expanding the label of Xalkori crizotinib from Pfizer to include treatment of c-ros proto-oncogene 1 receptor tyrosine kinase ( ROS1)-positive advanced non-small cell lung canc...